SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

November 6, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Investor Presentation.

Further to our Letter dated October 31, 2026, we are enclosing herewith Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2026.

Kindly take the information on record.

Thanking you,

For Supriya Lifescience Limited

Prachi Suhas Sathe

Digitally signed by Prachi Suhas Sathe
Date: 2026.11.06 13:14:05 +05'30'

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office *:* 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: **supriya@supriyalifescience .com** Website: **www.supriyalifescience.com**

Factory *:* A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



SUPRIYA LIFESCIENCE LTD.

SUPRIYA LIFESCIENCE LTD.

Q2 & H1 FY27 Investor Presentation


Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Supriya Lifescience Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



Q2 & H1FY27 Highlights

SUPRIYA LIFESCIENCE LTD.

Q2 FY27 Highlights


SUPRIYA LIFESCIENCE LTD.

Quarterly

Revenue	EBITDA	PBT	PAT
INR 2,063.0 Mn	INR 454.0 Mn	INR 377.8 Mn	INR 292.5 Mn
▲ 3.2% YoY	▼ 37.5% YoY	▼ 44.7% YoY	▼ 42.0% YoY

Regional Performance

Business Mix Revenue Contribution – By Region



H1 FY27 Highlights


SUPRIYA LIFESCIENCE LTD.

Quarterly

Revenue	EBITDA	PBT	PAT
INR 3,960.4 Mn	INR 928.6 Mn	INR 785.7 Mn	INR 532.9 Mn
▲ 14.8% YoY	▼ 25.3% YoY	▼ 32.1% YoY	▼ 37.5% YoY

Regional Performance

Business Mix Revenue Contribution – By Region




Q2 & H1 FY27 - Y-o-Y Highlights


SUPRIYA LIFESCIENCE LTD.

(in INR Mn)


Revenue




EBITDA




PBT




PAT



EBITDA Margins




PAT Margins



Business Mix Revenue Contribution – By Therapy

SUPRIYA LIFESCIENCE LTD.

Performance of the Top Therapeutic Areas



Profit & Loss Statement

SUPRIYA LIFESCIENCE LTD.

Particulars *(INR Mn)*	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q	H1 FY27	H1 FY26	Y-o-Y
Revenue from Operations	**2,063.0**	**1,998.3**	**3.2%**	**1,897.5**	**8.7%**	**3,960.4**	**3,449.1**	**14.8%**
Cost of Goods Sold	710.6	557.3	27.5%	563.9	26.0%	1,274.5	875.0	45.6%
Employee Benefits Expense	261.4	244.8	6.8%	284.9	-8.2%	546.3	471.7	15.8%
Other Expenses	636.9	469.8	35.6%	574.1	10.9%	1,211.1	858.9	41.0%
EBITDA	**454.0**	**726.5**	**-37.5%**	**474.6**	**-4.3%**	**928.6**	**1,243.5**	**-25.3%**
EBITDA %	**22.0%**	**36.4%**	**-1,435 bps**	**25.0%**	**-300 bps**	**23.4%**	**36.1%**	**-1,261 bps**
Other Income	22.9	27.2	-15.9%	26.5	-13.4%	49.4	54.0	-8.5%
Depreciation and Amortisation Expense	94.6	66.4	42.5%	89.4	5.8%	184.0	130.9	40.6%
EBIT	**382.4**	**687.3**	**-44.4%**	**411.7**	**-7.1%**	**794.0**	**1,166.6**	**-31.9%**
Finance Costs	4.6	4.1	10.3%	3.7	22.5%	8.3	9.3	-10.3%
PBT	**377.8**	**683.2**	**-44.7%**	**407.9**	**-7.4%**	**785.7**	**1,157.3**	**-32.1%**
Total Tax Expense	85.3	178.9	-52.3%	167.5	-49.1%	252.8	305.1	-17.2%
Profit for the year	**292.5**	**504.3**	**-42.0%**	**240.4**	**21.7%**	**532.9**	**852.2**	**-37.5%**
PAT %	**14.2%**	**25.2%**	**-1,106 bps**	**12.7%**	**151 bps**	**13.5%**	**24.7%**	**-1,125 bps**
EPS (INR)	5.04	6.30		2.99		6.62	10.59	

Balance Sheet

SUPRIYA LIFESCIENCE LTD.

INR Mn

Assets	Mar 26	Sep 26
Non-current assets		
(i) Property, plant and equipment	6,833	7,286
(ii) Right to Use Asset	45	48
(iii)Capital Work in progress	355	71
(iv) Intangible Assets	13	12
(v) Financial Assets		
-Investments	985	1,066
-Loans and Advances	-	-
(vi) Other Non- Current Assets	16	28
Total Non-current assets	**8,248**	**8,512**
Current assets		
(i) Inventories	1,596	2,652
(ii) Financial Assets		
-Trade receivables	2,194	1,256
-Cash and cash equivalents	375	410
-Bank balances other than above	413	349
-Other financial Assets	-	-
-Loans and Advances	6	5
(iii) Other current assets	738	1,033
Total Current Assets	**5,323**	**5,705**
TOTAL ASSETS	**13,571**	**14,217**

Equity and Liabilities	Mar 26	Sep 26
Equity		
(i) Equity share capital	161	161
(ii) Other equity	11,816	12,265
Total Equity	**11,977**	**12,426**
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	-	-
-Lease Liabilities	52	55
-Other financial liabilities	-	-
(ii) Provisions	19	15
(iii) Deferred tax Liabilities	312	416
Total Non-Current Liabilities	**383**	**487**
Current liabilities		
(i) Financial liabilities		
-Borrowings	-	-
-Lease Liabilities	2	3
-Trade payables	1,108	1,071
-Other financial liabilities	20	107
(iii) Provisions	17	9
(ii) Other current liabilities	62	114
Total Current Liabilities	**1,210**	**1,304**
TOTAL EQUITY AND LIABILITIES	**13,571**	**14,217**



Company Overview

SUPRIYA LIFESCIENCE LTD.

Business Overview

SUPRIYA LIFESCIENCE LTD.

Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics

40+ APIs Niche product basket	**120+** Countries Diversified operations with presence	**35,000** Sq.mts Manufacturing facility spread across	**932** KLPD Reactor capacity
WHO-GMP, Written Confirmation, ISO, Halal, Indonesian Halal. Fami QS	**40+** Years of excellence in manufacturing	**80%** Q2FY27 Revenue from exports	**1,500+** customers

U.S. FOOD & DRUG ADMINISTRATION — 4 Times approved

edqm COUNCIL OF EUROPE CONSEIL DE L'EUROPE — 2 times approved

Health Canada

Cofepris

ANVISA — 2 Times approved

KFDA Korea Food & Drug Administration 식품의약품안전청

NMPA 国家药品监督管理局 National Medical Products Administration

Australian Government Department of Health

AIFA AGENZIA ITALIANA DEL FARMACO

Journey So Far

SUPRIYA LIFESCIENCE LTD.

2022
CEP (Certificate of suitability) renewed for Pheniramine Maleate, Chlorpheniramine Maleate and Ketamine Hydrochloridec

2023
The Company commenced operations at its **new R&D lab in Lote Parshuram**

2024
ANVISA Approval Granted

2025
Launch of three molecules including Liquid Anesthesia

2026
Commercialized CMO facility at Ambernath

4th USFDA approval received for Lote Facility

2021
CEP granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate; Health Canada approval

Listed on Stock Exchange BSE & NSE

2020
Third time USFDA approval

2018
CEP granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride

2017
CEP granted for Pheniramine Maleate; **Second time USFDA approval granted**

2015
EUGMP and **EDQM** approval granted

2014
USFDA approval granted; IDL granted for Brompheniramine Maleate

2008
Incorporation & conversion from a partnership firm to a public limited company

2009
Started production of Ketamine hydrochloride

2010
CEP granted for Chlorphenamine Maleate

2011
IDL granted for Chlorphenamine Maleate

2013
COFEPRIS and **KFDA** approval granted

Backward Integrated Business Model

SUPRIYA LIFESCIENCE LTD.

Supply Security

Steady supply of essential raw materials

Low Price Risk

Protection against market fluctuations

In-House Processes

Less Dependence On External Parties

Cost-competitive Structure

Increasing margins

20 products are backward integrated* in following therapies

Anesthetics	Anti-Asthmatic	Anti-Histamine
Decongestant	Anti-Gout	

Note: In the process of further backward integrating of more products

74%


of H1FY27 revenue

Our integrated business model enables revenue growth while sustaining margins. A significant portion of this growth and resilience is driven by our backward-integrated product portfolio.



** As on 30th September 2026*

Diversified Geographic Presence



Presence in 120+ Countries Across Globe

FY27 Product Updates

Liquid Anesthetic

Two new anesthetic liquid inhalation products launched from Ambernath in Q2FY27; scale-up expected in the coming quarters.

ADHD

Planning ~2 launches in ADHD

FY26 Product Updates

Cardio Vascular

The product launched in Q3FY26 has witnessed a ramp-up

ADHD

The product is scaling-up, backed by healthy demand from LATAM and Europe, with momentum expected to continue


Liquid Anesthetic

Steady monthly supplies continue as planned

Diversified Revenues with Extensive Global Presence


Significant export presence, with low dependence on a specific geography

Export sales, as a % of revenue from operations



... with balanced customer concentration

Share of top 10 customers, as a % of revenue from operations



Long standing relationship with global pharma companies ...

... We plan to further reduce customer concentration

Penetration of existing products to newer geographies by registering these products

Adding new niche products with high volume potential for which we have 2 new R&D centers

CMO/CDMO opportunities

Advanced Manufacturing

SUPRIYA LIFESCIENCE LTD.

- Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, warehouse, raw materials, packaging materials and finished goods stores
- Recently commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
- Commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
- **Strategic Land Acquisitions:**
  - **12,551 sq.mt.**: Adjacent to the existing facility to enable seamless future growth and expansion
  - **24,646 sq.mt.**: Located 20 km from the current facility, strategically acquired for backward integration to enhance operational efficiency
  - **80,000 sq.mt.**: Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.

5
Manufacturing Blocks

9
Clean Rooms


932 KLPD
Reactor Capacity

35,000 sq.mt.
Land Area

Scaled up Manufacturing Facilities over the years

	Block A	Block B	Block C	Block D	Block E
Year of Establishment	**1993**	**1994**	**2014**	**2021**	**2024**
Capacities	157 KLPD	195 KLPD	30 KLPD	215 KLPD	335 KLPD
Regulatory Approved	✓	✓	✓	✓	✓

Healthy capacity utilization



Ambernath Facility

SUPRIYA LIFESCIENCE LTD.

Facility Location

- The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Additional Ambernath MIDC, District Thane, Maharashtra.
- Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.

R&D

- Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms.
- Analytical laboratories & Complex API synthesis facilities alongside dosage forms development for efficiency.
- Focus therapies – complex forms, anti-diabetics, anesthetics, vitamins and supplements, aesthetics among others.

Manufacturing

- FDF facilities commissioned.
- Tablets, capsules, liquids, nasal, inhalation, injections.
- Large volume liquids filling line.
- Validation and registration batches for dossier submissions.





RECENT DEVELOPMENTS

01 Launched two new anesthetic liquid inhalation products

02 EU audit scheduled for November 2026

03 Commercial manufacturing commenced; exhibit batch order received for RoW markets

R&D Capabilities

DSIR approved facility

4*
Process Patent Filed in India

Supported by R&D driven mindset

- A team of 68+ scientists primarily focused on API and formulations process development across the value chain
- Already started two R&D centres –
  - Ambernath R&D – Formulations and Generic APIs
  - Lote R&D – Lifecycle improvement
- Consistent efforts to develop new products, improve existing formulations, enhance drug delivery systems, and expand product applications
- Ongoing efforts to add 3-4 products every year






** As of March 2026*

CMO Capabilities

SUPRIYA LIFESCIENCE LTD.

- State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
- Complete support in validation, stability, & compilation of dossiers
- Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
- Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions
- Recently added Kilolab to strengthen capabilities in high-value small-molecule APIs





Complex Chemistries & Reaction (1/2)

SUPRIYA LIFESCIENCE LTD.

Focus on uniform manufacturing standards to achieve standardised product quality across markets

Ability to handle complex chemistries..

- Simple to highly complex chiral molecules
- Controlled substances
- Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
- Precision distillation of volatile inhaled Anesthetic APIs yielding high purity > 99.97%.

... across varied class of reactions

High vacuum distillations

Cyclisation

Grignard reaction

Fridel craft acylation

Decyanation

Etherification

Formylation

High pressure catalytic reductions

Bromination

Nitration

Oxirane

Lithiation

Complex Chemistries & Reaction (2/2)

SUPRIYA LIFESCIENCE LTD.

Focus on uniform manufacturing standards to achieve standardised product quality across markets

Ability to handle complex chemistries..

- Contrast media API synthesis
- Use of Resin for purification
- Novel amide formation techniques using low price reagents
- Handling of highly moisture sensitive API and intermediates

... across varied class of reactions

Chiral molecules synthesis using Chiral auxiliary

Amidation via Mixed anhydride

Reductive amination

Chlorination

Contrast media API

Distillation for purification

Asymmetric catalytic reduction

Resin chemistry for purification

Resolution

Thermal cyclization

Debenzylation

Regulatory Achievements

SUPRIYA LIFESCIENCE LTD.

Strong focus on compliance guided by ethical approach

- Our motto is to consistently meet the stringent requirements of regulatory bodies
- Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.

50+
Registrations in different countries

22
USDMF's

10
CADIFA Brazil

4
NMPA China

500+
Customer Audit Approvals

16
CEPs

7
KDMF Korea

50+
ROW

Awards & Accreditation

SUPRIYA LIFESCIENCE LTD.

2016

- Export House for the Year for 2015-16 awarded by Directorate of
- Industries, Government of Maharashtra
- Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra

2017


- Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
- Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra

2019

- Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of Indi
- 'Bharatiya Mahanatam Vikas Puraskar' for the year 2018-19 from Asia One Magazine.
- 'Outstanding Export Performance Award' for the year 2018-19 from Pharmaceuticals Export Promotion Council of India.

2025

- PMA Eminence Award 2025 in category Exporter of the Year from Pune Management Association on 27th May 2025 at Auto Cluster Auditorium, Pune.
- "The Diamond Jubilee All India Export Excellence Awards" by Federation of Industries of India on 27th May 2025 at Federation House, Thane.


Federation of Indian Export Organisations
is pleased to Award
"NIRYAT SHREE"
Certificate of Excellence
to Supriya Lifesciences Ltd (Mumbai)
for outstanding Export Performance in the category
of Chemicals, Drugs, Pharma and Allied Products - MSME
during the year 2008-09


Pharmaceuticals Export Promotion Council of India
OUTSTANDING EXPORT PERFORMANCE AWARD
Certificate
API / Bulk Drugs - Rising Star
Supriya Lifescience Limited
Mumbai, India


भारत सरकार
MSME
राष्ट्रीय पुरस्कार-2010
Government of India
Ministry of Micro, Small & Medium Enterprises
NATIONAL AWARD - 2010
Research & Development
Micro & Small Enterprises
Special Recognition Award
Shri Satish Waman Wagh
M/s Supriya Life Science Ltd.
Ratnagiri, MAHARASHTRA


CERTIFICATE OF EXPORT
RECOGNITION
Awarded to
Supriya Lifescience Ltd. (Ratnagiri)
in appreciation of their
export achievement in respect
of the following product group
EXPORT HOUSE
for the year 2015-16
Dr. Harshadeep Kamble (I.A.S.)

Key Management Team

SUPRIYA LIFESCIENCE LTD.



Satish Wagh

Executive Chairman & WTD

- An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University.
- B.Sc. from R.D National College and W.A. Science College, University of Bombay.
- Director on the board of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.



Saloni Wagh

Managing Director

- Ph.D. in chemistry from the Faculty of Science, Pacific University, Udaipur.
- M.Sc. from Institute of Science, University of Mumbai.
- B.Sc. from Parle Tilak Vidhyalaya Association's Sathaye College, University of Mumbai.



Shivani Wagh

Joint Managing Director

- Master's degree in International Business Management from Manchester Business School, University of Manchester.
- Bachelor's degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai.



Krishna Raghunathan

Chief Financial Officer

- Chartered Accountant (CA) from ICAI
- Bachelor degree of Science in Zoology from Madras University.
- Previously associated with companies like Dr. Reddy's Laboratories Limited and Granules India Limited.

EHS

SUPRIYA LIFESCIENCE LTD.



Environment

- Strict monitoring for high-efficiency pollution control; focus on solvent recovery and reduced emissions
- Strong reduce-recycle-reuse practices for resource conservation and waste minimization
- ETP Capacity – 400 KLPD with 2,000 KL retention; CETP discharge – 260 KLPD
- ~56% reduction in fuel/oil consumption over the years
- ERP implementation significantly reduced paper usage



Health

- Clean, safe and healthy working environment for our all employees
- Mandatory medical examination and periodic medical checkup
- Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.



Safety

- Commitment to safe, accident-free operations across facilities
- Regular safety training, fire drills, and strict policy adherence
- Periodic internal and external safety audits
- Advanced safety measures: closed pneumatic transfer, safer material substitutes, robust work permits, and process control systems

Received CDP "B" Rating, ISO Certification 14000 and 45001 and EcoVadis - Silver

CSR & Social Work

SUPRIYA LIFESCIENCE LTD.

We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm

- Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
- Supporting and participating with NGOs in chosen fields
- Utilization of CSR funding for drinking water scarcity in villages near our factory site
- Contribution to Prime Minister National Relief Fund
- Support patients for cancer treatment
- Fund raisers and donations to worthy social causes, etc.





Historical Financial Performance


SUPRIYA LIFESCIENCE LTD.

Consistent & Strong Financial Performance


SUPRIYA LIFESCIENCE LTD.

(in INR Mn)


Robust revenue growth




Capex Spend




... and, focus on profitability



Return on Net Worth



Healthy leverage profile (x)*




*Note: Leverage profile is defined as the ratio of Debt to Equity, where Debt includes both current and non-current borrowings and lease liabilities, while Equity represents total shareholders' equity.

Working Capital Break-up


SUPRIYA LIFESCIENCE LTD.

(in days)


Inventory




Receivables



Payables



Net Working Capital





Future Outlook

SUPRIYA
LIFESCIENCE LTD.

Future Outlook

SUPRIYA LIFESCIENCE LTD.

R&D centres

API R&D -

- Ambernath API R&D facility fully commissioned with a team of 16 scientists
- Equipped with advanced instrumentation (HRMS/MS, GC-MS/MS, HPLC, GC, FTIR) enabling robust development
- Capability to develop 3–4 APIs using cost-competitive and sustainable technologies
- Supports captive finished dosage division through new product development and supply
- Strong focus on innovation and IP creation, with two patents filed this year

Finished Dosage R&D -

- 30 products under development across tablets, capsules, injections, and inhalation liquids
- Five exhibits completed; progressing towards 10 product exhibits
- Novel Semaglutide tablet formulation developed and protected through patent

CMO/CDMO space

- Evaluating opportunity for exclusive manufacturing rights in liquid inhalation products
- GLP-1 portfolio development and supply in progress for a leading Indian generics company
- Novel combination product under discussion with an innovator partner
- Multiple opportunities under active negotiation for finished dosage development and supply

New markets

- Expanded API customer base across Japan, EU, and US, while strengthening existing relationships through continuous product additions
- Regulatory filings in EU and US underway to enable long-term contracts and market expansion
- Agreements secured in South Asia and supplies initiated for ROW markets from finished dosage division
- Regulatory approvals in progress (EU-GMP, COFEPRIS, Health Canada) alongside dossier filings across multiple markets
- Plan to file six dossiers in the EU during the current financial year

Capacity enhancement

- New vitamin product block successfully commissioned. Civil work initiated for debottlenecking across all production blocks for capacity enhancement and new F block will be added
- Five finished dosage manufacturing lines operational
- Capacity expansion planned with addition of a new production block at Lote
- New nasal line planned to strengthen finished dosage capabilities

Supriya Lifescience Limited
CIN: L51900MH2008PLC180452
Mr. Krishna Raghunathan - Chief Financial Officer
cfo@supriyalifescience.com
www.supriyalifescience.com

Ernst & Young LLP

Runjhun Jain
+91 98207 20993
runjhun.jain1@in.ey.com

Sneha Salian
+91 98194 30437
sneha2.salian@in.ey.com



THANK YOU